| Subject |
Fespixon is included in the "DAROC Clinical Practice Guidelines For Type 2 Diabetes Care 2022" (2024 update) |
- Date of occurrence of the event: 2024/07/02
- Company name: ONENESS BIOTECH CO., LTD.
- Relationship to the Company (please enter ”head office” or ”subsidiaries”): head office
- Reciprocal shareholding ratios: NA
- Cause of occurrence: Oneness' new drug ”Fespixon” has been included in the ”Diabetic Foot” section in ”Chapter 15 - Microvascular Complications of Diabetes and Diabetic Foot” of the ”Clinical Practice Guidelines For Type 2 Diabetes Care 2022 (2024 update)” compiled by the Diabetes Association of the Republic of China (Taiwan) (DAROC). The paragraph is as follows: ”The ON101 cream (trade name: Fespixon) developed by Taiwanese researchers has demonstrated its mechanism in reshaping the balance of pro-inflammatory (M1) and pro-healing/pro-remodeling (M2) macrophages in wound microenvironments to promote ulcer healing, supported by international multicenter phase III clinical trial results. It provides an treatment option for diabetic foot ulcer patients following perfusion improvement, wound debridement, and infection control.” The updated guidelines are published on the website of DAROC.
- Countermeasures: None
- Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): The inclusion of ”Fespixon”in the clinical practice guidelines allows physicians to understand the product and to provide this treatment option to diabetic foot ulcer patients.
|
